Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer

Journal of the National Cancer Institute

Volumn 107, Issue 6, 2015, Pages

  Pérez Gómez, Eduardo ^a,b   Andradas, Clara ^a,b   Blasco Benito, Sandra ^a,b   Caffarel, María M ^a,c   García Taboada, Elena ^a   Villa Morales, María ^d,e,f,j   Moreno, Estefanía ^g,h   Hamann, Sigrid ⁱ   Martín Villar, Ester ^j   Flores, Juana M ^a   Wenners, Antonia ⁱ   Alkatout, Ibrahim ⁱ   Klapper, Wolfram ⁱ   Röcken, Christoph ⁱ   Bronsert, Peter ^k   Stickeler, Elmar ^k   Staebler, Annette ^l   Bauer, Maret ⁱ   Arnold, Norbert ⁱ   Soriano, Joaquim ^m   Pérez Martínez, Manuel ^m   Megías, Diego ^m   Moreno Bueno, Gema ^j,n   Ortega Gutiérrez, Silvia ^a   Artola, Marta ^a   Vázquez Villa, Henar ^a   Quintanilla, Miguel ^j   Fernández Piqueras, José ^d,e,f   Canela, Enric I ^g,h   McCormick, Peter J ^g,h,o   Guzmán, Manuel ^a,g   Sánchez, Cristina ^a,b   more..

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Instituto de Investigación Hospital 12 de Octubre ^*  (Spain)

^c BASQUE FOUNDATION FOR SCIENCE   (Spain)

^d CSIC   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^f INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^g UNIVERSITY OF BARCELONA   (Spain)

^h CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

ⁱ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^j INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^k UNIVERSITY OF FREIBURG   (Germany)

^l UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^m Centro Nacional de Investigaciones Oncológicas   (Spain)

ⁿ MD ANDERSON CANCER CENTER   (Spain)

^o UNIVERSITY OF EAST ANGLIA   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 2 RECEPTOR; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ELK 1; CNR2 PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ANIMAL MODEL; ARTICLE; BIOASSAY; BREAST CANCER; BREAST CANCER CELL LINE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER TISSUE; CARCINOGENESIS; CHROMATIN IMMUNOPRECIPITATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOLOGY; DISTANT METASTASIS; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; ONCOGENE NEU; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROXIMITY LIGATION ASSAY; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; TISSUE MICROARRAY; TUMOR XENOGRAFT; UNIVERSITY HOSPITAL; ANIMAL; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; GERMANY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KAPLAN MEIER METHOD; METABOLISM; PROGNOSIS; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GERMANY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; MICE; PROGNOSIS; RECEPTOR, CANNABINOID, CB2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84930689586     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv077     Document Type: Article

References (55)

1. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346-352.
2. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
3. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874.
4. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003;100(18):10393-10398.
5. Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest. 2011;121(10):3797-3803.
6. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26(45):6469-6487.
7. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389-462.
8. Pertwee RG, Howlett AC, Abood ME, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol Rev. 2010;62(4):588-631.
9. Fowler CJ, Gustafsson SB, Chung SC, et al. Targeting the endocannabinoid system for the treatment of cancer-a practical view. Curr Top Med Chem. 2010;10(8):814-827.
10. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 2003;3(10):745-755.
11. Velasco G, Sanchez C, Guzman M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444.
12. Alpini G, Demorrow S. Changes in the endocannabinoid system may give insight into new and effective treatments for cancer. Vitam Horm. 2009;81:469-485.
13. Pisanti S, Bifulco M. Endocannabinoid system modulation in cancer biology and therapy. Pharmacol Res. 2009;60(2):107-116.
14. Caffarel MM, Andradas C, Perez-Gomez E, et al. Cannabinoids: A new hope for breast cancer therapy? Cancer Treat Rev. 2012;38(7):911-98.
15. Guindon J, Hohmann AG. The endocannabinoid system and cancer: Therapeutic implication. Br J Pharmacol. 2011;163(7):1447-1463.
16. Caffarel MM, Sarrio D, Palacios J, et al. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006;66(13):6615-6621.
17. Caffarel MM, Andradas C, Mira E, et al. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer. 2010;9:196.
18. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439(7074):353-357.
19. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10(6):529-541.
20. Gyorffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123(3):725-731.
21. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001;411(6841):1017-1021.
22. Cheng X, Xia W, Yang JY, et al. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochem Biophys Res Commun. 2010;403(1):103-107.
23. Muraoka RS, Lenferink AE, Law B, et al. ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol Cell Biol. 2002;22(7):2204-2219.
24. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436(7050):518-524.
25. Treisman R, Marais R, Wynne J. Spatial flexibility in ternary complexes between SRF and its accessory proteins. EMBO J. 1992;11(12):4631-4640.
26. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer. 2005;41(16):2462-2478.
27. Janknecht R, Hunter T. Convergence of MAP kinase pathways on the ternary complex factor Sap-1a. EMBO J. 1997;16(7):1620-1627.
28. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007;13(11):3207-3214.
29. Hatzis C, Pusztai L, Valero V, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011;305(18):1873-1881.
30. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007;25(10):1239-1246.
31. Miller LD, Smeds J, George J, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005;102(38):13550-13555.
32. Minn AJ, Gupta GP, Padua D, et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A. 2007;104(16):6740-6745.
33. Pawitan Y, Bjohle J, Amler L, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005;7(6):R953-R964.
34. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004;4(6):470-480.
35. Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci. 2012;33(3):122-128.
36. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009;6(10):587-595.
37. Almendro V, Garcia-Recio S, Gascon P. Tyrosine kinase receptor transactivation associated to G protein-coupled receptors. Curr Drug Targets. 2010;11(9):1169-1180.
38. Pyne NJ, Pyne S. Receptor tyrosine kinase-G-protein-coupled receptor signalling platforms: out of the shadow? Trends Pharmacol Sci. 2011;32(8):443-450.
39. Li YM, Pan Y, Wei Y, et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 2004;6(5):459-469.
40. Negro A, Brar BK, Gu Y, et al. erbB2 is required for G protein-coupled receptor signaling in the heart. Proc Natl Acad Sci U S A. 2006;103(43):15889-15893.
41. Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. 2013;13(9):663-673.
42. Donadelli M, Dando I, Zaniboni T, et al. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2011;2:e152.
43. Miyato H, Kitayama J, Yamashita H, et al. Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines. J Surg Res. 2009;155(1):40-47.
44. Torres S, Lorente M, Rodriguez-Fornes F, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther. 2011;10(1):90-103.
45. Gustafsson SB, Lindgren T, Jonsson M, et al. Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother Pharmacol. 2009;63(4):691-701.
46. Wheeler DL, Iida M, Dunn EF. The role of Src in solid tumors. Oncologist. 2009;14(7):667-678.
47. Aleshin A, Finn RS. SRC: A century of science brought to the clinic. Neoplasia. 2010;12(8):599-607.
48. Zhang S, Huang WC, Zhang L, et al. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res. 2013;73(18):5764-5774.
49. Zhang S, Huang WC, Li P, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 2011;17(4):461-469.
50. Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 2006;318(3):1375-1387.
51. Qamri Z, Preet A, Nasser MW, et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther. 2009;8(11):3117-3129.
52. Calatozzolo C, Salmaggi A, Pollo B, et al. Expression of cannabinoid receptors and neurotrophins in human gliomas. Neurol Sci. 2007;28(6):304-310.
53. Ellert-Miklaszewska A, Grajkowska W, Gabrusiewicz K, et al. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res. 2007;1137(1):161-169.
54. Sanchez C, de Ceballos ML, Gomez del Pulgar T, et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 2001;61(15):5784-5789.
55. Klein Nulent TJ, Van Diest PJ, van der Groep P, et al. Cannabinoid receptor-2 immunoreactivity is associated with survival in squamous cell carcinoma of the head and neck. Br J Oral Maxillofac Surg. 2013;51(7):604-609.